APRE (Aprea Therapeutics) FFO


APRE Aprea Therapeutics Inc APRE
30 GF Score
Price $0.81
! 1 Warning Sign
View Full Analysis

What is Aprea Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

APRE
30GF Score
Aprea Therapeutics Inc APRE
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aprea Therapeutics Business Description

Address 3805 Old Easton Road, Doylestown, PA, USA, 18902
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
30GF Score

Get the complete analysis for APRE

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.81
Price